MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

BIX-01294

產(chǎn)品活性：BIX-01294 是一種可逆且高度選擇性的 G9a 和 GLP 組蛋白甲基轉(zhuǎn)移酶抑制劑，IC₅₀ 分別為 1.9 μM 和 0.7 μM。BIX-01294 通過與底物賴氨酸殘基 N 端的氨基酸競爭結(jié)合來抑制 G9a/GLP。BIX-01294 是一種 (1H-1,4-diazepin-1-yl)-quinazolin-4-yl 胺衍生物，可誘導(dǎo)壞死性凋亡 (necroptosis) 和自噬。BIX-01294 在復(fù)發(fā)性腫瘤細胞中具有抗腫瘤活性。

研究領(lǐng)域：Epigenetics  |  Autophagy

作用靶點：Histone Methyltransferase  |  Autophagy

In Vitro: BIX-01294 (2 μM; 48 h) selectively inhibits recurrent tumor cell growth.
BIX-01294 (1 μM) leads to a marked increase in phosphorylation of S345 of MLKL.
BIX-01294 (1 μM) significantly upregulates the canonical p53 targets Cdkn1a (p21) and Gadd45a in recurrent tumor cell lines.
BIX-01294 (1 μM; 6 days) causes the reduction in H3K9me2 levels in primary and recurrent tumor cells.
BIX-01294 leads to necroptotic cell death in recurrent tumor cells. Necrostatin-1 (30 μM) partially reverses cell death induced by BIX-01294 (750 nM; 24 h).
BIX-01294 (4.1 μM; for 2 days) causes around a 20% reduction, concomitant with a comparable increase in the unmodified H3K9 fragment in H3K9me2 in mouse ES cells. BIX-01294 causes pronounced reduction in H3K9me2 and a small decrease for H3K9me3 and H3K9me1 in wild-type ES cells.
BIX-01294 has no inhibition of the other histone methyltransferases even at concentrations of 45 μM. BIX-01294 does not affect SUV39H1 (H320R) and PRMT1 within the tested concentration range (up to 10 μM).
BIX-01294 inhibits G9a in an uncompetitive manner with S-adenosyl-methionine (SAM).
BIX-01294 (1 µg/mL) causes reduction in the BrdU incorporation of fetal PASMCs. BIX-01294 treatment decreases the PASMCs migration induced by PDGF.

In Vivo: BIX-01294 (10 mg/kg; IP; three times a week for 2 weeks) significantly reduces tumor growth and tumor burden in recurrent tumor cells. Primary tumor growth is not inhibited.

相關(guān)產(chǎn)品：Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Reprogramming Compound Library  |  Anti-Blood Cancer Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  PRMT5-IN-17  |  EZM0414  |  WDR5-IN-5  |  PRMT5-IN-22  |  Gambogenic acid  |  SGC707  |  Dot1L-IN-7  |  MS1943  |  PRMT5-IN-21  |  NSD3-IN-3  |  DCLX069  |  MAK683  |  DS-437  |  EPZ020411  |  WDR5-IN-4 TFA  |  Amodiaquine dihydrochloride  |  Furamidine  |  SMYD3-IN-2  |  UNC0642  |  Chaetocin  |  UNC0646  |  UNC0224  |  EBI-2511  |  BVT948  |  MM-401  |  CMP-5  |  EPZ-719

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫，我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團隊跟蹤最新的制藥及生命科學(xué)研究進展，為您提供全球新的活性化合物；
•   與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。